nodes	percent_of_prediction	percent_of_DWPC	metapath
Fludarabine—RRM1—Hydroxyurea—psoriasis	0.762	1	CbGbCtD
Fludarabine—DCK—Desoximetasone—Clobetasol propionate—psoriasis	0.000415	0.0833	CbGdCrCtD
Fludarabine—DCK—Diflorasone—Clobetasol propionate—psoriasis	0.000403	0.0809	CbGdCrCtD
Fludarabine—DCK—Desoximetasone—Fluocinonide—psoriasis	0.000333	0.0667	CbGdCrCtD
Fludarabine—DCK—Desoximetasone—Beclomethasone—psoriasis	0.000333	0.0667	CbGdCrCtD
Fludarabine—DCK—Desoximetasone—Fluocinolone Acetonide—psoriasis	0.000323	0.0648	CbGdCrCtD
Fludarabine—DCK—Diflorasone—Beclomethasone—psoriasis	0.000323	0.0648	CbGdCrCtD
Fludarabine—DCK—Diflorasone—Fluocinonide—psoriasis	0.000323	0.0648	CbGdCrCtD
Fludarabine—POLA1—Leading Strand Synthesis—PCNA—psoriasis	0.000319	0.0571	CbGpPWpGaD
Fludarabine—POLA1—Removal of the Flap Intermediate—PCNA—psoriasis	0.000319	0.0571	CbGpPWpGaD
Fludarabine—DCK—Diflorasone—Fluocinolone Acetonide—psoriasis	0.000314	0.0629	CbGdCrCtD
Fludarabine—POLA1—Norethindrone—Hydrocortisone—psoriasis	0.000291	0.0584	CbGdCrCtD
Fludarabine—POLA1—Processive synthesis on the lagging strand—PCNA—psoriasis	0.000287	0.0513	CbGpPWpGaD
Fludarabine—POLA1—G1/S-Specific Transcription—PCNA—psoriasis	0.000273	0.0489	CbGpPWpGaD
Fludarabine—DCK—Purine metabolism—CAT—psoriasis	0.000255	0.0456	CbGpPWpGaD
Fludarabine—POLA1—Levonorgestrel—Hydrocortisone—psoriasis	0.000231	0.0464	CbGdCrCtD
Fludarabine—POLA1—Lagging Strand Synthesis—PCNA—psoriasis	0.000231	0.0413	CbGpPWpGaD
Fludarabine—POLA1—Telomere C-strand (Lagging Strand) Synthesis—PCNA—psoriasis	0.000214	0.0384	CbGpPWpGaD
Fludarabine—POLA1—Extension of Telomeres—PCNA—psoriasis	0.000178	0.0319	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000172	0.0308	CbGpPWpGaD
Fludarabine—RRM1—Nucleotide metabolism—CAT—psoriasis	0.000166	0.0298	CbGpPWpGaD
Fludarabine—POLA1—DNA strand elongation—PCNA—psoriasis	0.000165	0.0295	CbGpPWpGaD
Fludarabine—DCK—Desoximetasone—Hydrocortisone—psoriasis	0.000163	0.0328	CbGdCrCtD
Fludarabine—POLA1—E2F mediated regulation of DNA replication—PCNA—psoriasis	0.000161	0.0288	CbGpPWpGaD
Fludarabine—DCK—Desoximetasone—Betamethasone—psoriasis	0.000152	0.0304	CbGdCrCtD
Fludarabine—DCK—Desoximetasone—Dexamethasone—psoriasis	0.000152	0.0304	CbGdCrCtD
Fludarabine—DCK—Desoximetasone—Triamcinolone—psoriasis	0.000148	0.0297	CbGdCrCtD
Fludarabine—DCK—Diflorasone—Betamethasone—psoriasis	0.000147	0.0295	CbGdCrCtD
Fludarabine—DCK—Diflorasone—Dexamethasone—psoriasis	0.000147	0.0295	CbGdCrCtD
Fludarabine—DCK—Diflorasone—Triamcinolone—psoriasis	0.000144	0.0288	CbGdCrCtD
Fludarabine—DCK—Desoximetasone—Prednisone—psoriasis	0.000141	0.0282	CbGdCrCtD
Fludarabine—DCK—Desoximetasone—Prednisolone—psoriasis	0.000137	0.0275	CbGdCrCtD
Fludarabine—DCK—Diflorasone—Prednisone—psoriasis	0.000136	0.0274	CbGdCrCtD
Fludarabine—DCK—Diflorasone—Prednisolone—psoriasis	0.000133	0.0267	CbGdCrCtD
Fludarabine—SLC28A3—SLC-mediated transmembrane transport—CP—psoriasis	0.000133	0.0238	CbGpPWpGaD
Fludarabine—POLA1—DNA Replication—PCNA—psoriasis	0.000132	0.0237	CbGpPWpGaD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—PCNA—psoriasis	0.000131	0.0235	CbGpPWpGaD
Fludarabine—DCK—Nucleotide metabolism—CAT—psoriasis	0.000128	0.0229	CbGpPWpGaD
Fludarabine—Anaphylactic shock—Prednisolone—psoriasis	0.000116	0.00051	CcSEcCtD
Fludarabine—Oedema—Prednisolone—psoriasis	0.000116	0.00051	CcSEcCtD
Fludarabine—Dysuria—Methotrexate—psoriasis	0.000116	0.000509	CcSEcCtD
Fludarabine—Neutropenia—Methotrexate—psoriasis	0.000116	0.000509	CcSEcCtD
Fludarabine—Upper respiratory tract infection—Methotrexate—psoriasis	0.000115	0.000506	CcSEcCtD
Fludarabine—Paraesthesia—Cyclosporine—psoriasis	0.000115	0.000503	CcSEcCtD
Fludarabine—Cough—Triamcinolone—psoriasis	0.000114	0.000502	CcSEcCtD
Fludarabine—Dyspnoea—Cyclosporine—psoriasis	0.000114	0.0005	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000113	0.000498	CcSEcCtD
Fludarabine—Oedema—Hydrocortisone—psoriasis	0.000113	0.000498	CcSEcCtD
Fludarabine—Anaphylactic shock—Hydrocortisone—psoriasis	0.000113	0.000498	CcSEcCtD
Fludarabine—Convulsion—Triamcinolone—psoriasis	0.000113	0.000498	CcSEcCtD
Fludarabine—Asthenia—Mycophenolic acid—psoriasis	0.000113	0.000497	CcSEcCtD
Fludarabine—Infection—Hydrocortisone—psoriasis	0.000113	0.000495	CcSEcCtD
Fludarabine—Dyspepsia—Cyclosporine—psoriasis	0.000112	0.000493	CcSEcCtD
Fludarabine—Hyperhidrosis—Prednisolone—psoriasis	0.000112	0.000493	CcSEcCtD
Fludarabine—Nausea—Hydroxyurea—psoriasis	0.000112	0.000491	CcSEcCtD
Fludarabine—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000112	0.000491	CcSEcCtD
Fludarabine—Pruritus—Mycophenolic acid—psoriasis	0.000112	0.00049	CcSEcCtD
Fludarabine—Myalgia—Triamcinolone—psoriasis	0.000111	0.000489	CcSEcCtD
Fludarabine—Nervous system disorder—Hydrocortisone—psoriasis	0.000111	0.000489	CcSEcCtD
Fludarabine—Pneumonia—Methotrexate—psoriasis	0.000111	0.000489	CcSEcCtD
Fludarabine—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000111	0.000488	CcSEcCtD
Fludarabine—Decreased appetite—Cyclosporine—psoriasis	0.000111	0.000487	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Cyclosporine—psoriasis	0.00011	0.000484	CcSEcCtD
Fludarabine—Ill-defined disorder—Betamethasone—psoriasis	0.00011	0.000484	CcSEcCtD
Fludarabine—Ill-defined disorder—Dexamethasone—psoriasis	0.00011	0.000484	CcSEcCtD
Fludarabine—Discomfort—Triamcinolone—psoriasis	0.00011	0.000483	CcSEcCtD
Fludarabine—Fatigue—Cyclosporine—psoriasis	0.00011	0.000483	CcSEcCtD
Fludarabine—Hyperhidrosis—Hydrocortisone—psoriasis	0.00011	0.000482	CcSEcCtD
Fludarabine—Stevens-Johnson syndrome—Methotrexate—psoriasis	0.00011	0.000482	CcSEcCtD
Fludarabine—Dyspepsia—Mycophenolate mofetil—psoriasis	0.00011	0.000481	CcSEcCtD
Fludarabine—Pain—Cyclosporine—psoriasis	0.000109	0.000479	CcSEcCtD
Fludarabine—Constipation—Cyclosporine—psoriasis	0.000109	0.000479	CcSEcCtD
Fludarabine—Renal failure—Methotrexate—psoriasis	0.000109	0.000477	CcSEcCtD
Fludarabine—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000108	0.000475	CcSEcCtD
Fludarabine—Anorexia—Hydrocortisone—psoriasis	0.000108	0.000475	CcSEcCtD
Fludarabine—Diarrhoea—Mycophenolic acid—psoriasis	0.000108	0.000474	CcSEcCtD
Fludarabine—Stomatitis—Methotrexate—psoriasis	0.000108	0.000473	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000107	0.000472	CcSEcCtD
Fludarabine—Malaise—Betamethasone—psoriasis	0.000107	0.00047	CcSEcCtD
Fludarabine—Malaise—Dexamethasone—psoriasis	0.000107	0.00047	CcSEcCtD
Fludarabine—Anaphylactic shock—Triamcinolone—psoriasis	0.000107	0.000469	CcSEcCtD
Fludarabine—Oedema—Triamcinolone—psoriasis	0.000107	0.000469	CcSEcCtD
Fludarabine—Constipation—Mycophenolate mofetil—psoriasis	0.000106	0.000468	CcSEcCtD
Fludarabine—Pain—Mycophenolate mofetil—psoriasis	0.000106	0.000468	CcSEcCtD
Fludarabine—Arrhythmia—Prednisone—psoriasis	0.000106	0.000466	CcSEcCtD
Fludarabine—Infection—Triamcinolone—psoriasis	0.000106	0.000466	CcSEcCtD
Fludarabine—Haematuria—Methotrexate—psoriasis	0.000105	0.000463	CcSEcCtD
Fludarabine—Feeling abnormal—Cyclosporine—psoriasis	0.000105	0.000462	CcSEcCtD
Fludarabine—Alopecia—Prednisone—psoriasis	0.000105	0.000461	CcSEcCtD
Fludarabine—RRM1—Fluoropyrimidine Activity—TP53—psoriasis	0.000105	0.0188	CbGpPWpGaD
Fludarabine—Epistaxis—Methotrexate—psoriasis	0.000104	0.000458	CcSEcCtD
Fludarabine—Paraesthesia—Prednisolone—psoriasis	0.000104	0.000458	CcSEcCtD
Fludarabine—Malnutrition—Prednisone—psoriasis	0.000103	0.000454	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000103	0.000454	CcSEcCtD
Fludarabine—Hyperhidrosis—Triamcinolone—psoriasis	0.000103	0.000454	CcSEcCtD
Fludarabine—Convulsion—Dexamethasone—psoriasis	0.000103	0.000452	CcSEcCtD
Fludarabine—Convulsion—Betamethasone—psoriasis	0.000103	0.000452	CcSEcCtD
Fludarabine—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000103	0.000451	CcSEcCtD
Fludarabine—Paraesthesia—Hydrocortisone—psoriasis	0.000102	0.000447	CcSEcCtD
Fludarabine—Myalgia—Betamethasone—psoriasis	0.000101	0.000444	CcSEcCtD
Fludarabine—Myalgia—Dexamethasone—psoriasis	0.000101	0.000444	CcSEcCtD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—PCNA—psoriasis	0.000101	0.0181	CbGpPWpGaD
Fludarabine—Body temperature increased—Cyclosporine—psoriasis	0.000101	0.000443	CcSEcCtD
Fludarabine—Vomiting—Mycophenolic acid—psoriasis	0.0001	0.000441	CcSEcCtD
Fludarabine—Discomfort—Dexamethasone—psoriasis	9.98e-05	0.000439	CcSEcCtD
Fludarabine—Discomfort—Betamethasone—psoriasis	9.98e-05	0.000439	CcSEcCtD
Fludarabine—Dyspepsia—Hydrocortisone—psoriasis	9.98e-05	0.000439	CcSEcCtD
Fludarabine—Haemoglobin—Methotrexate—psoriasis	9.97e-05	0.000438	CcSEcCtD
Fludarabine—Rash—Mycophenolic acid—psoriasis	9.94e-05	0.000437	CcSEcCtD
Fludarabine—Dermatitis—Mycophenolic acid—psoriasis	9.93e-05	0.000437	CcSEcCtD
Fludarabine—Pain—Prednisolone—psoriasis	9.93e-05	0.000436	CcSEcCtD
Fludarabine—Haemorrhage—Methotrexate—psoriasis	9.92e-05	0.000436	CcSEcCtD
Fludarabine—SLC29A1—SLC-mediated transmembrane transport—CP—psoriasis	9.89e-05	0.0177	CbGpPWpGaD
Fludarabine—Headache—Mycophenolic acid—psoriasis	9.88e-05	0.000434	CcSEcCtD
Fludarabine—Decreased appetite—Hydrocortisone—psoriasis	9.86e-05	0.000433	CcSEcCtD
Fludarabine—Pharyngitis—Methotrexate—psoriasis	9.85e-05	0.000433	CcSEcCtD
Fludarabine—Body temperature increased—Mycophenolate mofetil—psoriasis	9.84e-05	0.000432	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Hydrocortisone—psoriasis	9.79e-05	0.00043	CcSEcCtD
Fludarabine—Fatigue—Hydrocortisone—psoriasis	9.77e-05	0.00043	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Triamcinolone—psoriasis	9.73e-05	0.000427	CcSEcCtD
Fludarabine—Pain—Hydrocortisone—psoriasis	9.69e-05	0.000426	CcSEcCtD
Fludarabine—Oedema—Betamethasone—psoriasis	9.69e-05	0.000426	CcSEcCtD
Fludarabine—Oedema—Dexamethasone—psoriasis	9.69e-05	0.000426	CcSEcCtD
Fludarabine—Anaphylactic shock—Betamethasone—psoriasis	9.69e-05	0.000426	CcSEcCtD
Fludarabine—Anaphylactic shock—Dexamethasone—psoriasis	9.69e-05	0.000426	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	9.67e-05	0.0173	CbGpPWpGaD
Fludarabine—Infection—Betamethasone—psoriasis	9.62e-05	0.000423	CcSEcCtD
Fludarabine—Infection—Dexamethasone—psoriasis	9.62e-05	0.000423	CcSEcCtD
Fludarabine—Ill-defined disorder—Prednisone—psoriasis	9.59e-05	0.000421	CcSEcCtD
Fludarabine—SLC29A1—Fluoropyrimidine Activity—TP53—psoriasis	9.59e-05	0.0172	CbGpPWpGaD
Fludarabine—Paraesthesia—Triamcinolone—psoriasis	9.59e-05	0.000421	CcSEcCtD
Fludarabine—Feeling abnormal—Prednisolone—psoriasis	9.57e-05	0.00042	CcSEcCtD
Fludarabine—Visual impairment—Methotrexate—psoriasis	9.56e-05	0.00042	CcSEcCtD
Fludarabine—Anaemia—Prednisone—psoriasis	9.55e-05	0.00042	CcSEcCtD
Fludarabine—DCK—Levonorgestrel—Hydrocortisone—psoriasis	9.54e-05	0.0191	CbGdCrCtD
Fludarabine—Dyspnoea—Triamcinolone—psoriasis	9.52e-05	0.000418	CcSEcCtD
Fludarabine—Nervous system disorder—Betamethasone—psoriasis	9.5e-05	0.000417	CcSEcCtD
Fludarabine—Nervous system disorder—Dexamethasone—psoriasis	9.5e-05	0.000417	CcSEcCtD
Fludarabine—Agitation—Prednisone—psoriasis	9.5e-05	0.000417	CcSEcCtD
Fludarabine—Thrombocytopenia—Dexamethasone—psoriasis	9.48e-05	0.000417	CcSEcCtD
Fludarabine—Thrombocytopenia—Betamethasone—psoriasis	9.48e-05	0.000417	CcSEcCtD
Fludarabine—Hypersensitivity—Cyclosporine—psoriasis	9.4e-05	0.000413	CcSEcCtD
Fludarabine—Dyspepsia—Triamcinolone—psoriasis	9.4e-05	0.000413	CcSEcCtD
Fludarabine—Erythema multiforme—Methotrexate—psoriasis	9.38e-05	0.000412	CcSEcCtD
Fludarabine—Nausea—Mycophenolic acid—psoriasis	9.37e-05	0.000412	CcSEcCtD
Fludarabine—Hyperhidrosis—Dexamethasone—psoriasis	9.36e-05	0.000411	CcSEcCtD
Fludarabine—Hyperhidrosis—Betamethasone—psoriasis	9.36e-05	0.000411	CcSEcCtD
Fludarabine—Feeling abnormal—Hydrocortisone—psoriasis	9.34e-05	0.000411	CcSEcCtD
Fludarabine—Malaise—Prednisone—psoriasis	9.32e-05	0.00041	CcSEcCtD
Fludarabine—Anorexia—Dexamethasone—psoriasis	9.23e-05	0.000406	CcSEcCtD
Fludarabine—Anorexia—Betamethasone—psoriasis	9.23e-05	0.000406	CcSEcCtD
Fludarabine—Fatigue—Triamcinolone—psoriasis	9.2e-05	0.000404	CcSEcCtD
Fludarabine—Hypersensitivity—Mycophenolate mofetil—psoriasis	9.17e-05	0.000403	CcSEcCtD
Fludarabine—Asthenia—Cyclosporine—psoriasis	9.15e-05	0.000402	CcSEcCtD
Fludarabine—Pain—Triamcinolone—psoriasis	9.13e-05	0.000401	CcSEcCtD
Fludarabine—Pruritus—Cyclosporine—psoriasis	9.03e-05	0.000397	CcSEcCtD
Fludarabine—Body temperature increased—Hydrocortisone—psoriasis	8.96e-05	0.000394	CcSEcCtD
Fludarabine—Convulsion—Prednisone—psoriasis	8.96e-05	0.000394	CcSEcCtD
Fludarabine—Asthenia—Mycophenolate mofetil—psoriasis	8.93e-05	0.000392	CcSEcCtD
Fludarabine—Chills—Methotrexate—psoriasis	8.9e-05	0.000391	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Betamethasone—psoriasis	8.82e-05	0.000388	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Dexamethasone—psoriasis	8.82e-05	0.000388	CcSEcCtD
Fludarabine—Pruritus—Mycophenolate mofetil—psoriasis	8.8e-05	0.000387	CcSEcCtD
Fludarabine—Arthralgia—Prednisone—psoriasis	8.8e-05	0.000387	CcSEcCtD
Fludarabine—Myalgia—Prednisone—psoriasis	8.8e-05	0.000387	CcSEcCtD
Fludarabine—Feeling abnormal—Triamcinolone—psoriasis	8.8e-05	0.000387	CcSEcCtD
Fludarabine—Alopecia—Methotrexate—psoriasis	8.77e-05	0.000385	CcSEcCtD
Fludarabine—Diarrhoea—Cyclosporine—psoriasis	8.73e-05	0.000384	CcSEcCtD
Fludarabine—Paraesthesia—Betamethasone—psoriasis	8.7e-05	0.000382	CcSEcCtD
Fludarabine—Paraesthesia—Dexamethasone—psoriasis	8.7e-05	0.000382	CcSEcCtD
Fludarabine—Discomfort—Prednisone—psoriasis	8.69e-05	0.000382	CcSEcCtD
Fludarabine—Malnutrition—Methotrexate—psoriasis	8.64e-05	0.00038	CcSEcCtD
Fludarabine—Hypersensitivity—Prednisolone—psoriasis	8.55e-05	0.000376	CcSEcCtD
Fludarabine—Dyspepsia—Dexamethasone—psoriasis	8.53e-05	0.000375	CcSEcCtD
Fludarabine—Dyspepsia—Betamethasone—psoriasis	8.53e-05	0.000375	CcSEcCtD
Fludarabine—Diarrhoea—Mycophenolate mofetil—psoriasis	8.51e-05	0.000374	CcSEcCtD
Fludarabine—Body temperature increased—Triamcinolone—psoriasis	8.44e-05	0.000371	CcSEcCtD
Fludarabine—Anaphylactic shock—Prednisone—psoriasis	8.44e-05	0.000371	CcSEcCtD
Fludarabine—Oedema—Prednisone—psoriasis	8.44e-05	0.000371	CcSEcCtD
Fludarabine—Decreased appetite—Betamethasone—psoriasis	8.42e-05	0.00037	CcSEcCtD
Fludarabine—Decreased appetite—Dexamethasone—psoriasis	8.42e-05	0.00037	CcSEcCtD
Fludarabine—Infection—Prednisone—psoriasis	8.38e-05	0.000368	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Dexamethasone—psoriasis	8.36e-05	0.000367	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Betamethasone—psoriasis	8.36e-05	0.000367	CcSEcCtD
Fludarabine—Hypersensitivity—Hydrocortisone—psoriasis	8.35e-05	0.000367	CcSEcCtD
Fludarabine—Fatigue—Betamethasone—psoriasis	8.35e-05	0.000367	CcSEcCtD
Fludarabine—Fatigue—Dexamethasone—psoriasis	8.35e-05	0.000367	CcSEcCtD
Fludarabine—Pain—Dexamethasone—psoriasis	8.28e-05	0.000364	CcSEcCtD
Fludarabine—Pain—Betamethasone—psoriasis	8.28e-05	0.000364	CcSEcCtD
Fludarabine—Nervous system disorder—Prednisone—psoriasis	8.27e-05	0.000364	CcSEcCtD
Fludarabine—Hyperhidrosis—Prednisone—psoriasis	8.15e-05	0.000358	CcSEcCtD
Fludarabine—Asthenia—Hydrocortisone—psoriasis	8.13e-05	0.000357	CcSEcCtD
Fludarabine—Vomiting—Cyclosporine—psoriasis	8.11e-05	0.000356	CcSEcCtD
Fludarabine—POLA1—Telomere Maintenance—PCNA—psoriasis	8.07e-05	0.0145	CbGpPWpGaD
Fludarabine—Rash—Cyclosporine—psoriasis	8.04e-05	0.000353	CcSEcCtD
Fludarabine—Anorexia—Prednisone—psoriasis	8.04e-05	0.000353	CcSEcCtD
Fludarabine—Dermatitis—Cyclosporine—psoriasis	8.04e-05	0.000353	CcSEcCtD
Fludarabine—Pruritus—Hydrocortisone—psoriasis	8.02e-05	0.000352	CcSEcCtD
Fludarabine—Ill-defined disorder—Methotrexate—psoriasis	8.01e-05	0.000352	CcSEcCtD
Fludarabine—Headache—Cyclosporine—psoriasis	7.99e-05	0.000351	CcSEcCtD
Fludarabine—Anaemia—Methotrexate—psoriasis	7.98e-05	0.000351	CcSEcCtD
Fludarabine—Feeling abnormal—Dexamethasone—psoriasis	7.98e-05	0.000351	CcSEcCtD
Fludarabine—Feeling abnormal—Betamethasone—psoriasis	7.98e-05	0.000351	CcSEcCtD
Fludarabine—Vomiting—Mycophenolate mofetil—psoriasis	7.91e-05	0.000348	CcSEcCtD
Fludarabine—Hypersensitivity—Triamcinolone—psoriasis	7.86e-05	0.000346	CcSEcCtD
Fludarabine—Rash—Mycophenolate mofetil—psoriasis	7.85e-05	0.000345	CcSEcCtD
Fludarabine—Dermatitis—Mycophenolate mofetil—psoriasis	7.84e-05	0.000344	CcSEcCtD
Fludarabine—Headache—Mycophenolate mofetil—psoriasis	7.8e-05	0.000343	CcSEcCtD
Fludarabine—Malaise—Methotrexate—psoriasis	7.79e-05	0.000342	CcSEcCtD
Fludarabine—Diarrhoea—Hydrocortisone—psoriasis	7.76e-05	0.000341	CcSEcCtD
Fludarabine—Leukopenia—Methotrexate—psoriasis	7.73e-05	0.00034	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Prednisone—psoriasis	7.69e-05	0.000338	CcSEcCtD
Fludarabine—Asthenia—Triamcinolone—psoriasis	7.66e-05	0.000337	CcSEcCtD
Fludarabine—Body temperature increased—Betamethasone—psoriasis	7.66e-05	0.000336	CcSEcCtD
Fludarabine—Body temperature increased—Dexamethasone—psoriasis	7.66e-05	0.000336	CcSEcCtD
Fludarabine—Nausea—Cyclosporine—psoriasis	7.58e-05	0.000333	CcSEcCtD
Fludarabine—Paraesthesia—Prednisone—psoriasis	7.57e-05	0.000333	CcSEcCtD
Fludarabine—Pruritus—Triamcinolone—psoriasis	7.55e-05	0.000332	CcSEcCtD
Fludarabine—Cough—Methotrexate—psoriasis	7.54e-05	0.000331	CcSEcCtD
Fludarabine—Convulsion—Methotrexate—psoriasis	7.48e-05	0.000329	CcSEcCtD
Fludarabine—Dyspepsia—Prednisone—psoriasis	7.43e-05	0.000326	CcSEcCtD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—PCNA—psoriasis	7.39e-05	0.0132	CbGpPWpGaD
Fludarabine—Nausea—Mycophenolate mofetil—psoriasis	7.39e-05	0.000325	CcSEcCtD
Fludarabine—Arthralgia—Methotrexate—psoriasis	7.35e-05	0.000323	CcSEcCtD
Fludarabine—Myalgia—Methotrexate—psoriasis	7.35e-05	0.000323	CcSEcCtD
Fludarabine—Decreased appetite—Prednisone—psoriasis	7.33e-05	0.000322	CcSEcCtD
Fludarabine—Rash—Prednisolone—psoriasis	7.32e-05	0.000322	CcSEcCtD
Fludarabine—Dermatitis—Prednisolone—psoriasis	7.31e-05	0.000321	CcSEcCtD
Fludarabine—Fatigue—Prednisone—psoriasis	7.27e-05	0.00032	CcSEcCtD
Fludarabine—Headache—Prednisolone—psoriasis	7.27e-05	0.00032	CcSEcCtD
Fludarabine—Discomfort—Methotrexate—psoriasis	7.27e-05	0.000319	CcSEcCtD
Fludarabine—Constipation—Prednisone—psoriasis	7.21e-05	0.000317	CcSEcCtD
Fludarabine—Vomiting—Hydrocortisone—psoriasis	7.21e-05	0.000317	CcSEcCtD
Fludarabine—Rash—Hydrocortisone—psoriasis	7.15e-05	0.000314	CcSEcCtD
Fludarabine—Dermatitis—Hydrocortisone—psoriasis	7.14e-05	0.000314	CcSEcCtD
Fludarabine—Confusional state—Methotrexate—psoriasis	7.11e-05	0.000312	CcSEcCtD
Fludarabine—Headache—Hydrocortisone—psoriasis	7.1e-05	0.000312	CcSEcCtD
Fludarabine—Anaphylactic shock—Methotrexate—psoriasis	7.05e-05	0.00031	CcSEcCtD
Fludarabine—Infection—Methotrexate—psoriasis	7e-05	0.000308	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	7e-05	0.0125	CbGpPWpGaD
Fludarabine—Feeling abnormal—Prednisone—psoriasis	6.95e-05	0.000305	CcSEcCtD
Fludarabine—Asthenia—Betamethasone—psoriasis	6.95e-05	0.000305	CcSEcCtD
Fludarabine—Asthenia—Dexamethasone—psoriasis	6.95e-05	0.000305	CcSEcCtD
Fludarabine—Nervous system disorder—Methotrexate—psoriasis	6.91e-05	0.000304	CcSEcCtD
Fludarabine—Thrombocytopenia—Methotrexate—psoriasis	6.9e-05	0.000303	CcSEcCtD
Fludarabine—Nausea—Prednisolone—psoriasis	6.9e-05	0.000303	CcSEcCtD
Fludarabine—Pruritus—Dexamethasone—psoriasis	6.85e-05	0.000301	CcSEcCtD
Fludarabine—Pruritus—Betamethasone—psoriasis	6.85e-05	0.000301	CcSEcCtD
Fludarabine—POLA1—Synthesis of DNA—PCNA—psoriasis	6.83e-05	0.0122	CbGpPWpGaD
Fludarabine—Hyperhidrosis—Methotrexate—psoriasis	6.82e-05	0.000299	CcSEcCtD
Fludarabine—Vomiting—Triamcinolone—psoriasis	6.79e-05	0.000298	CcSEcCtD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—CP—psoriasis	6.74e-05	0.0121	CbGpPWpGaD
Fludarabine—Nausea—Hydrocortisone—psoriasis	6.73e-05	0.000296	CcSEcCtD
Fludarabine—Rash—Triamcinolone—psoriasis	6.73e-05	0.000296	CcSEcCtD
Fludarabine—Dermatitis—Triamcinolone—psoriasis	6.72e-05	0.000296	CcSEcCtD
Fludarabine—POLA1—Chromosome Maintenance—PCNA—psoriasis	6.72e-05	0.012	CbGpPWpGaD
Fludarabine—Anorexia—Methotrexate—psoriasis	6.72e-05	0.000295	CcSEcCtD
Fludarabine—Headache—Triamcinolone—psoriasis	6.69e-05	0.000294	CcSEcCtD
Fludarabine—Body temperature increased—Prednisone—psoriasis	6.67e-05	0.000293	CcSEcCtD
Fludarabine—Diarrhoea—Betamethasone—psoriasis	6.63e-05	0.000291	CcSEcCtD
Fludarabine—Diarrhoea—Dexamethasone—psoriasis	6.63e-05	0.000291	CcSEcCtD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—CARM1—psoriasis	6.43e-05	0.0115	CbGpPWpGaD
Fludarabine—Musculoskeletal discomfort—Methotrexate—psoriasis	6.42e-05	0.000282	CcSEcCtD
Fludarabine—POLA1—DNA Replication—PCNA—psoriasis	6.41e-05	0.0115	CbGpPWpGaD
Fludarabine—Nausea—Triamcinolone—psoriasis	6.34e-05	0.000279	CcSEcCtD
Fludarabine—Paraesthesia—Methotrexate—psoriasis	6.33e-05	0.000278	CcSEcCtD
Fludarabine—Dyspnoea—Methotrexate—psoriasis	6.28e-05	0.000276	CcSEcCtD
Fludarabine—POLA1—Mitotic M-M/G1 phases—PTTG1—psoriasis	6.26e-05	0.0112	CbGpPWpGaD
Fludarabine—Hypersensitivity—Prednisone—psoriasis	6.21e-05	0.000273	CcSEcCtD
Fludarabine—Dyspepsia—Methotrexate—psoriasis	6.21e-05	0.000273	CcSEcCtD
Fludarabine—POLA1—G1/S Transition—PCNA—psoriasis	6.17e-05	0.0111	CbGpPWpGaD
Fludarabine—Vomiting—Betamethasone—psoriasis	6.16e-05	0.000271	CcSEcCtD
Fludarabine—Vomiting—Dexamethasone—psoriasis	6.16e-05	0.000271	CcSEcCtD
Fludarabine—Decreased appetite—Methotrexate—psoriasis	6.13e-05	0.000269	CcSEcCtD
Fludarabine—Rash—Betamethasone—psoriasis	6.11e-05	0.000268	CcSEcCtD
Fludarabine—Rash—Dexamethasone—psoriasis	6.11e-05	0.000268	CcSEcCtD
Fludarabine—Dermatitis—Betamethasone—psoriasis	6.1e-05	0.000268	CcSEcCtD
Fludarabine—Dermatitis—Dexamethasone—psoriasis	6.1e-05	0.000268	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Methotrexate—psoriasis	6.09e-05	0.000267	CcSEcCtD
Fludarabine—Fatigue—Methotrexate—psoriasis	6.08e-05	0.000267	CcSEcCtD
Fludarabine—Headache—Dexamethasone—psoriasis	6.07e-05	0.000267	CcSEcCtD
Fludarabine—Headache—Betamethasone—psoriasis	6.07e-05	0.000267	CcSEcCtD
Fludarabine—Asthenia—Prednisone—psoriasis	6.05e-05	0.000266	CcSEcCtD
Fludarabine—Pain—Methotrexate—psoriasis	6.03e-05	0.000265	CcSEcCtD
Fludarabine—Pruritus—Prednisone—psoriasis	5.97e-05	0.000262	CcSEcCtD
Fludarabine—RRM1—Metabolism—NDUFA5—psoriasis	5.91e-05	0.0106	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	5.88e-05	0.0105	CbGpPWpGaD
Fludarabine—Feeling abnormal—Methotrexate—psoriasis	5.81e-05	0.000255	CcSEcCtD
Fludarabine—Diarrhoea—Prednisone—psoriasis	5.77e-05	0.000254	CcSEcCtD
Fludarabine—Nausea—Dexamethasone—psoriasis	5.75e-05	0.000253	CcSEcCtD
Fludarabine—Nausea—Betamethasone—psoriasis	5.75e-05	0.000253	CcSEcCtD
Fludarabine—POLA1—S Phase—PCNA—psoriasis	5.6e-05	0.01	CbGpPWpGaD
Fludarabine—Body temperature increased—Methotrexate—psoriasis	5.57e-05	0.000245	CcSEcCtD
Fludarabine—Vomiting—Prednisone—psoriasis	5.36e-05	0.000236	CcSEcCtD
Fludarabine—Rash—Prednisone—psoriasis	5.32e-05	0.000234	CcSEcCtD
Fludarabine—Dermatitis—Prednisone—psoriasis	5.31e-05	0.000234	CcSEcCtD
Fludarabine—Headache—Prednisone—psoriasis	5.28e-05	0.000232	CcSEcCtD
Fludarabine—POLA1—Mitotic G1-G1/S phases—PCNA—psoriasis	5.2e-05	0.00932	CbGpPWpGaD
Fludarabine—Hypersensitivity—Methotrexate—psoriasis	5.19e-05	0.000228	CcSEcCtD
Fludarabine—Asthenia—Methotrexate—psoriasis	5.06e-05	0.000222	CcSEcCtD
Fludarabine—RRM1—Metabolism—CYP2S1—psoriasis	5.03e-05	0.00901	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—CP—psoriasis	5.03e-05	0.009	CbGpPWpGaD
Fludarabine—Nausea—Prednisone—psoriasis	5.01e-05	0.00022	CcSEcCtD
Fludarabine—Pruritus—Methotrexate—psoriasis	4.99e-05	0.000219	CcSEcCtD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—TP53—psoriasis	4.83e-05	0.00865	CbGpPWpGaD
Fludarabine—Diarrhoea—Methotrexate—psoriasis	4.82e-05	0.000212	CcSEcCtD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—CARM1—psoriasis	4.79e-05	0.00859	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—PTTG1—psoriasis	4.68e-05	0.00839	CbGpPWpGaD
Fludarabine—DCK—Metabolism—NDUFA5—psoriasis	4.55e-05	0.00815	CbGpPWpGaD
Fludarabine—Vomiting—Methotrexate—psoriasis	4.48e-05	0.000197	CcSEcCtD
Fludarabine—Rash—Methotrexate—psoriasis	4.44e-05	0.000195	CcSEcCtD
Fludarabine—Dermatitis—Methotrexate—psoriasis	4.44e-05	0.000195	CcSEcCtD
Fludarabine—Headache—Methotrexate—psoriasis	4.42e-05	0.000194	CcSEcCtD
Fludarabine—Nausea—Methotrexate—psoriasis	4.19e-05	0.000184	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—PTTG1—psoriasis	4.19e-05	0.0075	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.94e-05	0.00706	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	3.9e-05	0.00698	CbGpPWpGaD
Fludarabine—DCK—Metabolism—CYP2S1—psoriasis	3.87e-05	0.00693	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	3.75e-05	0.00672	CbGpPWpGaD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—TP53—psoriasis	3.71e-05	0.00665	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	3.41e-05	0.0061	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	3.31e-05	0.00593	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	2.92e-05	0.00523	CbGpPWpGaD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—TP53—psoriasis	2.72e-05	0.00487	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	2.57e-05	0.00461	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—CARM1—psoriasis	2.46e-05	0.0044	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.2e-05	0.00393	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.11e-05	0.00379	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.92e-05	0.00344	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—PCNA—psoriasis	1.91e-05	0.00342	CbGpPWpGaD
Fludarabine—DCK—Metabolism—CARM1—psoriasis	1.89e-05	0.00338	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—PCNA—psoriasis	1.71e-05	0.00306	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.64e-05	0.00295	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—CAT—psoriasis	1.51e-05	0.00271	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.45e-05	0.0026	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—APOE—psoriasis	1.17e-05	0.0021	CbGpPWpGaD
Fludarabine—DCK—Metabolism—CAT—psoriasis	1.16e-05	0.00208	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PPARG—psoriasis	1.02e-05	0.00183	CbGpPWpGaD
Fludarabine—DCK—Metabolism—APOE—psoriasis	9.03e-06	0.00162	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PPARG—psoriasis	7.86e-06	0.00141	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—TP53—psoriasis	6.27e-06	0.00112	CbGpPWpGaD
